Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX310 in Refractory Dyslipidemias
NCT07491172Phase 1Recruiting
- Sponsor
- CRISPR Therapeutics
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Gene Silencing, CRISPR-Cas9, Lipid-based Nanoparticles
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of CTX310 in dyslipidemia, sponsored by CRISPR Therapeutics. Primary endpoint: Safety and Tolerability at 12 months. Started Jun 2024; status: recruiting.
02
Drugs
CTX310
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT07491172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07491172.